Docetaxel Rechallenge in Patients with Castration-resistant Prostate Cancer – A Review
chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium [abstract], J Clin Oncol, 2011;29:Absract #133.
39. Ansari J, Hussain SA, Zarkar A, et al., Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience, Oncol Rep, 2008;20:891–6.
40. Soga N, Kato M, Nishikawa K, et al., Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients, Int J Clin Oncol, 2009;14:130–5.
41. Eymard JC, Oudard S, Gravis G, et al., Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study, BJU Int, 2010;106:974–8.
42. Loriot Y, Massard C, Gross-Goupil M, et al., The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer, Eur J Cancer, 2010;46:1770–2.
43. Caffo O, Pappagallo G, Brugnara S, et al., Multiple
rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors, Urology, 2012 (in press).
44. Mountzios I, Bournakis E, Efstathiou E, et al., Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer, Urology, 2011;77:682–7.
45. Gernone A, Pagliarulo A, Calderoni G, et al., Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment [abstract], J Clin Oncol, 2011;29:Abstract #161.
46. Fuxius S, Mueller A, Kleitz K, et al., Weekly docetaxel rechallenge in patients with hormone-resistant prostate cancer refractory to conventionally three weekly docetaxel [abstract], J Clin Oncol, 2010;28:Abstract #e15004
47. Markman M, Rothman R, Hakes T, et al., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J Clin Oncol, 1991;9:389–93.
48. Sevcenco S, Kramer G, Klatte T, et al., Predictors of response to docetaxel re-treatment in patients with castration resistant prostate cancer [abstract], Eur Urol, 2010;9:Abstract #C156.
49. Jancovic B, Beardsley E, Chi KN, Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic
hormone refractory prostate cancer (HRPC) after previous docetaxel: A population based analysis [abstract #196], Proc ASCO Genitourinary Cancers Symposium, San Francisco, 2008.
50. Heidenreich A, Pfister D, Thuer D, et al., Docetaxel rechallenge versus docetaxel/bevacizumabin castration- resistant prostate cancer following first-line docetaxel [abstract], J Clin Oncol, 2010;28:Absract #e15006.
51. Firek P, Pfister D, Thuer D, et al., Docetaxel rechallenge at PSA relapse after docetaxel chemotherapy at hormone- refractory prostate cancer [abstract #93], Proc 2010 ASCO Genitourinary Cancers Symposium, San Francisco, 2010.
52. Gernone A, Pagliarulo A, Pagliarulo V, Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC) [abstract], J Clin Oncol, 2010;28:Abstract e15020.
53. Bracarda S, Sisani M, Rossi M, et al., Docetaxel rechallenge chemotherapy in metastatic castration resistant prostate cancer (mCRPC) [abstract], J Clin Oncol, 2011;29:Abstract #e15145.
54. Robert L, Maroto J, Sebio A, et al., Docetaxel rechallenge in patients with prostate cancer progressing under castration levels of testosterone (PPuCT): A single-center study (abstract), J Clin Oncol, 2011;29:Abstract #e15105.
EUROPEAN ONCOLOGY & HAEMATOLOGY
41
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77